Skip to main navigation Skip to search Skip to main content

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis

Grants and Contracts Details

StatusFinished
Effective start/end date7/8/11 → 9/30/12

Funding

  • Agennix Inc: $34,714.00